Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.90 |
| ▸ | MET | P08581 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | GNRHR | P30968 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27317684 | 0.87 | CHKA (0.78) | CHKAMETKCNH2HRH3KMT2A | |
| SCHEMBL6741474 | 0.84 | CHKA (0.66) | CHKAMETMCHR1 | |
| SCHEMBL31429049 | 0.83 | CHKA (0.65) | CHKAMETKCNH2HRH3MCHR1 | |
| SCHEMBL31428708 | 0.83 | CHKA (0.64) | CHKAMETHRH3SMN1; SMN2 | |
| SCHEMBL14604923 | 0.83 | CHKA (0.64) | CHKAMETGNRHRSMN1; SMN2SLC6A4 | |
| SCHEMBL8320637 | 0.82 | CHKA (0.64) | CHKAMETKCNH2GNRHRADRA2A | |
| SCHEMBL9590379 | 0.81 | CHKA (0.62) | CHKAMETKCNH2HRH3MCHR1 | |
| SCHEMBL31428922 | 0.79 | CHKA (0.60) | CHKAMETKCNH2HRH3GNRHR | |
| SCHEMBL13499599 | 0.79 | CHKA (0.88) | CHKAHRH3MC4RKMT2A | |
| SCHEMBL25728287 | 0.78 | CHKA (0.59) | CHKAKCNH2HRH3MC4RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | CHKA 663/4885MET 4373/4885KCNH2 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.